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Abstract
Background: Colorectal cancer (CRC) is the second most prevalent type of cancer in Europe. Early detection and 
removal of CRC or its precursor lesions by population screening can reduce mortality. Colonoscopy and computed 
tomography colonography (CT colonography) are highly accurate exams and screening options that examine the 
entire colon. The success of screening depends on the participation rate. We designed a randomized trial to compare 
the uptake, yield and costs of direct colonoscopy population screening, using either a telephone consultation or a 
consultation at the outpatient clinic, versus CT colonography first, with colonoscopy in CT colonography positives.
Methods and design: 7,500 persons between 50 and 75 years will be randomly selected from the electronic database 
of the municipal administration registration and will receive an invitation to participate in either CT colonography 
(2,500 persons) or colonoscopy (5,000 persons) screening. Those invited for colonoscopy screening will be randomized 
to a prior consultation either by telephone or a visit at the outpatient clinic. All CT colonography invitees will have a 
prior consultation by telephone. Invitees are instructed to consult their general practitioner and not to participate in 
screening if they have symptoms suggestive for CRC. After providing informed consent, participants will be scheduled 
for the screening procedure. The primary outcome measure of this study is the participation rate. Secondary outcomes 
are the diagnostic yield, the expected and perceived burden of the screening test, level of informed choice and cost-
effectiveness of both screening methods.
Discussion: This study will provide further evidence to enable decision making in population screening for colorectal 
cancer.
Trial registration: Dutch trial register: NTR1829
Background
Colorectal cancer (CRC) is the second most prevalent
type of cancer in Europe. In 2006, 412,900 persons were
diagnosed with CRC and 207,400 persons died from the
disease[1]. In the Netherlands, more than 4,700 persons
died as a result of CRC in 2006[2,3]. The prognosis of
patients with CRC depends on the clinical and pathologi-
cal stage at the time of diagnosis. Early detection of CRC
reduces CRC-related mortality; early detection and
removal of its precursor lesions -adenomas- reduces both
the incidence and mortality of CRC[4]. Thus, population
screening of asymptomatic average risk persons can
reduce the mortality rate [5-8]. In addition, given the
high, rapidly rising costs of treatment of CRC, screening
has actually become cost saving[9].
The currently available options for colorectal cancer
screening are stool based tests (guaiac and immuno-
chemical faecal occult blood tests and faecal DNA tests)
and structural exams (flexible sigmoidoscopy, colonos-
copy, double contrast barium enema and CT colonogra-
phy). Colon capsule is another technique that examines
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Page 2 of 9the entire colon. However, this modality is currently not
accepted for CRC screening[10,11].
Randomized clinical trials evaluated guaiac-based
FOBT (gFOBT) screening during a 10-year screening
period and showed reduction in CRC-mortality[12].
Immunochemical FOBT (iFOBT) is considered a supe-
rior screening test, because of its better reproducibility
and acceptance. Detection rates for advanced adenomas
and cancer are higher compared to gFOBT[13]. Further-
more, iFOBT screening offers the option to select a cut-
off level matching the optimal performance of the test in
a given population with the available colonoscopy capac-
ity[14,15]. A new method of CRC screening that tests
DNA markers in stool (sDNA) may be a promising tool
for screening in the future. At this moment sDNA does
not provide any advantages as a screening method com-
pared with FOBT. Flexible sigmoidoscopy (FS) is an
endoscopic procedure, in which the distal 40-60 cm of
the colon is inspected. Total colonoscopy is advised in
case of positive findings. FS has a threefold higher detec-
tion rate for advanced neoplasia compared with
FOBT[16,17]. Double contrast barium enema (DCBE)
and capsule endoscopy can be considered as inferior
screening modalities than colonoscopy. Accuracy was
considerably lower and these techniques were not tested
in an average risk screening population[18,19].
Colonoscopy and CT colonography are structural
exams allowing inspection of the entire colon. Colonos-
copy is widely accepted as the clinical reference standard
for the detection of colorectal neoplasia and has the
advantage that removal of adenomas or early cancer can
be performed during the same procedure. All other
screening procedures require colonoscopy for confirma-
tion of a diagnosis and, if applicable, therapy (polypec-
tomy) in case of a positive test result. Furthermore,
colonoscopy screening can be performed with long inter-
vals since the risk of developing CRC after a negative
colonoscopy remains decreased for more than 10
years[20,21]. Despite the excellent sensitivity and speci-
ficity of colonoscopy, miss rates of 2.1% for large ade-
nomas (≥ 10 mm) are reported in tandem colonoscopy
studies[22]. A disadvantage of colonoscopy as a screening
method is its complication rate of 0.1 to 0.3% including
post polypectomy bleeding and perforation [23-25]. Sec-
ondly, colonoscopy is a burdensome procedure for which
full bowel cleansing is necessary. These factors together
explain the limited uptake of colonoscopy as a primary
screening test and the insufficient use of colonoscopy for
surveillance after previous adenoma removal[26]. Finally,
colonoscopy capacity is a limiting factor for its wide-
spread use as primary screening test.
CT colonography is a less invasive full colonic exam
which can be performed with limited bowel preparation
and could therefore be a good alternative in a screening
setting [27-29]. CT colonography has been demonstrated
to have a high sensitivity for the detection of CRC
(96%)[30]. A large screening trial evaluating CT colonog-
raphy and same day colonoscopy studied 1233 asymp-
tomatic individuals and reported high sensitivity (94%)
and specificity (96%) per patient for large adenomas (≥10
mm). Sensitivity and specificity for adenomas larger than
or equal to 6 mm was 89% and 80% respectively[31]. The
diagnostic yield for advanced neoplasia of CT colonogra-
phy (3.2%) was comparable to that of colonoscopy
(3.4%)[32]. The risk of complications is extremely low,
there were no perforations or other serious complications
in a large CT colonography screening cohort[32]. CT
colonography with limited bowel preparation has a lower
burden and is preferred by patients compared to regular
CT colonography[33]. A disadvantage of CT colonogra-
phy is the exposure of individuals to ionizing radiation.
However, the chances of radiation induced malignancy
are considered very low, especially when a low dose pro-
tocol is used. The detection of extracolonic findings in
CT colonography could be beneficial, but risks and costs
associated with false positives and inconsequential find-
ings may be substantial. Of all available screening tests for
CRC, colonoscopy and CT colonography are the most
accurate exams.
The optimal screening test for CRC is still a subject of
fierce debate. FOBT and FS are suboptimal tests whereas
full colonic exams, such as colonoscopy and CT colonog-
raphy are associated with risks, costs and high workload.
An evidence-based estimate of the participation rate is
essential for making predictions of the effectiveness and
costs of a population screening programme.
In the Netherlands, population based screening trials
by gFOBT, iFOBT and FS have already been performed.
Studies that investigated stool-based tests as a screening
method reported participation rates of 47-50% (gFOBT)
and 60-62% (iFOBT)[13,17]. FS-screening had a lower
participation rate of 32%[17].
We will conduct a study evaluating the participation
rate of both colonoscopy and CT colonography as a
screening method in a population-based programme.
Since colonoscopy is a more invasive procedure, partici-
pation in a colonoscopy screening programme can be
expected to be lower than in FOBT and FS screening[34].
On the other hand, FOBT and FS screening should be
repeated every 2 and 5 years and participation over a 10
years period could be considerably lower than for a single
round of screening[6]. Participation rates might be influ-
enced by the burden of the screening procedure itself and
its bowel preparation. We will therefore evaluate the
expected and actual perceived burden of both screening
methods, as well as the reasons to participate or not in
the screening programme.
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are invited for a prior consultation at the outpatient
clinic. In an effort to reduce the number of patients not
attending for colonoscopy, Rodger J et al. introduced a
consultation by telephone in a FOBT positive population
in a CRC screening programme and found a significant
reduction of 14.1%[35]. Therefore, we hypothesize that a
consultation by telephone instead of an appointment at
the outpatient clinic prior to colonoscopy could contrib-
ute to a higher participation rate in primary colonoscopy
screening. Screening invitees should be enabled to make
a well-informed decision to participate or not and we will
evaluate the level of informed choice in the decision mak-
ing process[36,37]. Since the expected costs and work-
load of a population based screening programme by
colonoscopy and CT colonography are serious concerns,
we will evaluate the cost-effectiveness and feasibility and
compare these with the other available screening tech-
niques in the Netherlands.
Methods and design
Objectives
Primary objective
To compare the participation rates in a population-based
screening programme for colorectal cancer by primary
colonoscopy and CT colonography.
Secondary objectives
• To compare the diagnostic yield of both screening tech-
niques (detection rates of cancer, advanced adenomas
and adenomas).
• To compare the expected and perceived burden of
colonoscopy and CT colonography.
• To compare the cost-effectiveness and feasibility of
colonoscopy and CT colonography as screening methods.
• To compare the level of informed choice in the deci-
sion-making process for (non-) participation in colonos-
copy and CT colonography screening.
Study design
This study will be a two-centre randomized controlled
trial. A cohort of 7,500 persons of the Amsterdam and
Rijnmond region will be randomly selected from the elec-
tronic database of the regional municipal administration
registrations (Gemeentelijke Basis Administratie (GBA)).
In total, 2,500 persons will be randomly selected to
receive an invitation for colonoscopy screening with a
prior consultation by telephone. Another 2,500 persons
will be randomly selected to receive an invitation for
colonoscopy screening with a prior consultation at the
outpatient clinic. A third group of 2,500 persons will be
randomly selected to receive an invitation for CT
colonography, with a prior consultation by telephone [fig-
ure 1]. Randomization will be performed per household,
stratified for age, sex and socio-economic status (SES).
Study population
Our study population consists of 7,500 individuals
between 50 and 75 years of age living in our target areas.
The selected areas comprise all SES-categories (very low,
low, average, high and very high) and are based on data of
Statistics Netherlands[3]. The target areas will not have
been selected for previous pilot trials on CRC screening.
Individuals with CRC symptoms in the previous three
months (rectal blood loss and/or changed bowel habits)
are advised in our information leaflet to consult their
general practitioner and to not participate in screening.
Persons who underwent full colonic examination in the
previous 5 years (complete colonoscopy and/or double
contrast barium enema) are also instructed not to partici-
pate and are excluded from the screening programme, as
well as individuals planned for surveillance colonoscopy,
because of personal history of colorectal cancer, colonic
adenomas or inflammatory bowel disease (IBD)). Persons
with a severe or terminal disease with a life-expectancy of
less than 5 years are excluded. Although pregnancy is not
likely in this cohort, pregnant women are also excluded.
For CT colonography, individuals exposed to ionizing
radiation for research purposes within the previous 12
months and individuals with hyperthyroidism are
excluded.
Invitation procedure
Similar to our previous CRC screening trials, a special-
ized database will be used for the logistics of the invita-
tional procedure. All invitations will be sent out between
June 2009 and September 2010 by the regional Compre-
hensive Cancer Centres in Amsterdam and Rotterdam.
Members of the target population will receive a pre-
announcement, followed by an invitation for the screen-
ing programme two weeks later, both by mail. Informa-
tion leaflet and reply card are sent together with the
invitation. All invitees have three options to respond: by
returning the reply-card, by calling the Comprehensive
Cancer Centre or by sending an e-mail. The Comprehen-
sive Cancer Centre will make an appointment for a prior
consultation. All non-respondents will receive a reminder
by mail 4 weeks after the initial invitation.
Information leaflet
Three different information leaflets will be used, one for
each arm. The information leaflet is an updated version
of the leaflet used in previous CRC screening trials in the
Amsterdam and Rijnmond region and modified for the
screening methods studied. The leaflet is based on the
principles of informed-choice, aiming to enable all
invited persons to make a well-informed decision
whether or not to participate. The leaflet consists of
information on CRC in general, the advantages and possi-
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case of a positive test result.
Prior consultation
Persons allocated to colonoscopy screening are invited
for a prior consultation either by telephone or at the out-
patient clinic. Prior to CT colonography, all invited indi-
viduals will receive a consultation by telephone. During
the consultation, they are informed about the screening
procedure, bowel preparation, possible risks and the fol-
low-up in case of a positive test result. A standardized
questionnaire is used to check on contra-indications and/
or exclusion criteria. If additional information is needed
regarding a possible exclusion criterion or contra-indica-
tion for the screening procedure, the general practitioner
or medical specialist will be contacted for further infor-
mation or the individual selected for intake by telephone
will be invited for a visit at the outpatient clinic. Individu-
als without contraindications will be scheduled for
screening at the regional CRC-screening centre. Subse-
quently, all colonoscopy screening participants will be
asked to perform an immunochemical FOBT.
Informed consent
Informed consent will be discussed during the prior con-
sultation. All participants are instructed to return the
informed consent form by mail before the scheduled
screening procedure.
Colonoscopy
All colonoscopies will be performed at one of the two
participating centres by gastroenterologists with an expe-
rience of 500 or more colonoscopies. The colonoscopy
will be performed taking the standard quality aspects into
account defined by the American Society for Gastrointes-
tinal Endoscopy[38]. All participants are prepared by a
low fibre diet and by oral intake of 2 L of transparent fluid
and 2 L of hypertonic polyethylene glycol solution (Mov-
iprep; Norgine bv, Amsterdam, The Netherlands) at
home. The procedures are performed under conscious
sedation using intravenous midazolam (Dormicum, Act-
avis, Baarn, The Netherlands) and fentanyl (Bipharma,
Weesp, The Netherlands) at the discretion of the partici-
pant and the endoscopist. In case of poor bowel prepara-
tion the colonoscopy is interrupted and postponed. Cecal
intubation by the colonoscope is confirmed by still
Figure 1 Design of the screening trial. Flow chart.
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intubation of the ileum. Insertion and withdrawal times
will be separately recorded. At the start of withdrawal of
the endoscope, butylscopalamine bromide (Buscopan,
Boehringer Ingelheim bv, Alkmaar, The Netherlands) will
be given intravenously at the discretion of the endosco-
pist to reduce colonic motility and repeated if necessary.
Inspection on withdrawal of the endoscope will be at
least 6 minutes[39]. All detected lesions will be removed
during the same procedure if possible. If immediate
endoscopic treatment is impossible, biopsies will be
obtained and pathological assessment of these tissue
samples will provide a definitive diagnosis.
Lesions
Of all detected lesions during colonoscopy the size (milli-
metres), morphology (sessile, pedunculated, flat or
depressed), localization (distance from the anus, segment
of the colon) and macroscopic aspect (hyperplastic, ade-
nomatous, carcinomatous) will be noted. The size of each
lesion is measured using an open biopsy forceps with 7
mm span. Furthermore, data on diagnostic or therapeutic
procedure (biopsy, piecemeal polypectomy, coagulation
or cold-snare total polypectomy), macroscopic involve-
ment of margins, use of saline and/or epinephrine, and
time needed for polypectomy will be recorded.
Pathology
Histology will be defined according to the Vienna crite-
ria[40]. Dysplasia will be defined as either low grade or
high grade and all lesions will be classified into hyperplas-
tic, serrated, tubular, tubulovillous, villous or carcinoma
lesion. Histopathology will be processed and stained
using standard methods and will be evaluated by two
expert pathologists (one in each centre). All advanced
neoplasias and a random selection of 10% of all other
lesions evaluated in each centre will be revised by the
pathologist of the other centre. In case of inconsistency,
the slides will be reviewed together to come to a definitive
diagnosis.
CT colonography
The preparation for CT colonography includes two times
50 mL of iodinated contrast agent (Telebrix, Guerbet,
Aulnay sous Bois, France) for tagging on the day prior to
the study and 50 mL 1.5 hour before the examination,
combined with a low-residue diet. This regimen resulted
in high image quality not distinct from a full bowel prepa-
ration[41]. Bowel preparation with tagging is now indi-
cated as best practice in the recently published
international CT colonography standards[42]. Colonic
distension will be obtained with an automatic carbon
dioxide insufflator (PROTOCO2L, Bracco, EZEM, Lake
Success, USA) after intravenous administration of 1 ml
butylscopalamine bromide. If butylscopalamine is con-
traindicated, 1 mg of glucagonhydrochloride (GlucaGen,
Novo Nordisk A'S, Bagsvaerd, Denmark) will be used
intravenously. If both butylscopalamine bromide and glu-
cagonhydrochloride are contraindicated, CT colonogra-
phy examination will be performed without bowel
relaxants. CT colonography will be performed with a 64-
slice CT scanner in one of the two participating centres
by qualified and experienced personnel. Images will be
obtained in both the supine and prone position, using a
low dose protocol with the following specifications: colli-
mation 64 × 0.625 mm, slice thickness 0.9 mm, recon-
struction interval 0.7 mm, tube voltage 120 kV and 25 ref
mAs supine and prone.
Each CT colonography is evaluated by one of the three
experienced physicians (two abdominal radiologists, one
research fellow) as well as two of the four experienced
technicians (prior experience ≥200 CT colonography
examinations with colonoscopic verification). Image pro-
cessing and interpretation is performed with the use of a
non-commercially available CT colonography worksta-
tion (View Forum, Demo version R6.1V1L1, Philips,
Eindhoven, The Netherlands). Primary 2D read will be
used, with endoluminal 3D problem solving and the use
of computer assisted detection (CAD) as a secondary
read. Lesion size will be measured on 3D images, unless
there is too much faecal material around the polyp, in
that case 2D measurements will be used.
Lesions
Both intra- and extracolonic findings will be recorded. A
true positive intracolonic CT colonography finding is
defined as a CT colonography lesion of at least 6 mm that
is found in the same or adjacent segment on the colonos-
copy with the size of the lesion at least <50% margin of
error.
Diminutive polyps (5 mm and smaller) will be ignored
as the chance for malignancy is very low. Of all intraco-
lonic lesions ≥ 6 mm, data on certainty (25%, 50%, 75%
and 100%), size, location and morphology (sessile, pedun-
culated, flat) will be documented. If referred for colonos-
copy, CT colonography results will be verified using
segmental unblinding and histopathology.
Extracolonic structures will be examined using the C-
RADS classification[43]. An extracolonic lesion of C-
RADS E3 (likely unimportant finding, incompletely char-
acterized) or E4 (potentially important finding) is consid-
ered to be clinically relevant.
Complications
Complications will be registered until 30 days after the
screening procedure. Complications of CT colonography
are defined as all complications occurring during CT
colonography as well as all complications of colonoscopy
in CT colonography positives. Of all complications the
timing, severity, relation to the procedure, treatment and
outcome will be reported. All participants will be inter-
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istry.
Follow-up after positive test result
Colonoscopy
All participants will be informed about the result of
colonoscopy on the day of the procedure. In the case of
polyps or cancer, histopathological assessment of tissue
samples will provide a definitive diagnosis and partici-
pants will be informed about the results within 2 weeks.
Advice regarding surveillance colonoscopy will be given
to persons according to the Dutch Institute for Health-
care Improvement (CBO) consensus[44]. In case of can-
cer, the patient is invited at the outpatient clinic and
referred to a gastroenterologist or surgeon for further
treatment. The general practitioner and participant will
receive a letter about the results of the colonoscopy and
corresponding follow-up if needed after two weeks.
CT colonography
All participants will be informed by telephone about the
results of CT colonography within 2 weeks. Both the par-
ticipant and the general practitioner will receive a letter
by mail with the findings at CT colonography. Individuals
with one or more lesions ≥10 mm at CT colonography
will be referred for colonoscopy, while individuals with
only lesions 6-9 mm in size will be advised to undergo
surveillance CT colonography. Surveillance CT colonog-
raphy will be advised after 1.5 years when there are three
or more 6-9 mm lesions and 3 years when there are one
or two 6-9 mm lesions. If referral for colonoscopy is
needed, the participant will be invited for a visit at the
outpatient clinic where information is given on the conse-
quences of the positive test result and if there are no con-
traindications a colonoscopy will be advised. If the
participant consents, a colonoscopy will be performed
within the following two weeks. Patients with relevant
extracolonic findings will be invited at the outpatient
clinic and referred for corresponding follow-up[43].
Questionnaires
At different time-points, questionnaires will be provided.
The first questionnaire is sent after the prior consultation
to all subjects scheduled for the screening test to assess
the following items: demographic and socioeconomic
status, satisfaction of the prior consultation, reasons for
participation, level of informed choice and expected bur-
den of the screening procedure (items 1-5, see below).
The same questionnaire is sent to all subjects not
responding to the first invitation (non-respondents),
together with the reminder, and to all non-participants to
obtain information about the reasons of non-participa-
tion. In case of low response, 10% of non-respondents
will be contacted by telephone to assess a shortened ver-
sion of this questionnaire. A second questionnaire is sent
to participants two weeks after the screening test and will
contain questions about the perceived burden of the
screening method (item 5).
1) Demographic and socioeconomic status
Baseline characteristics as age, gender, marital status, eth-
nicity, education and employment will be collected.
2) Satisfaction of the prior consultation
To evaluate the satisfaction of the prior consultation by
telephone compared with the prior consultation at the
outpatient clinic, items are included based on an existing
patient-satisfaction questionnaire[45].
3) Reasons for (non-)participation and understanding of the 
information leaflet
In the first and second Dutch pilots on screening for col-
orectal cancer with FOBT,[36,46,47] a questionnaire has
been developed to collect data on awareness of CRC, rea-
sons for (non-) participation and clarity and readability of
the information leaflet. As in the second round of FOBT
screening, the Health Belief Model (HBM) is used as the-
oretical background to understand the reasons for (non-)
participation[36,48]. The corresponding items are
adjusted for this study.
4) Informed choice
To evaluate the proportions of participants and non-par-
ticipants who made their decision on the basis of an
informed choice, it is required to assess the knowledge,
attitude and uptake of the invited persons. Items con-
cerning knowledge and attitude are derived from both
Dutch FOBT pilots [13,36], and from the evaluation of
prenatal and lung cancer screening in the Netherlands
which is based on Marteau's measure of informed choice
[49-51].
5) Expected and perceived burden of the screening procedure
The experience of participants with the screening proce-
dure is evaluated with a questionnaire assessing anxiety,
embarrassment, pain and discomfort. The items assess
the perception of participants regarding the bowel prepa-
ration and the burden of the screening procedure itself.
Responses are scored on a standard formatted five-point
Likert scale. Satisfaction with the screening procedure
will be measured by items scored on a 4-point scale.
This questionnaire is based on questionnaires used in
the first and second Dutch pilot for screening with
FOBT[34,36] and on studies investigating the acceptance
of CT colonography[34] and patient perception of diag-
nostic tests for faecal incontinence[52], as well as on pre-
vious discrete choice experiments showing that especially
type of bowel preparation, risk education of CRC related
death and length of screening interval influence CRC
screening preferences[37].
Cost-effectiveness
Cost-effectiveness will be evaluated by incorporating the
final results in the validated MISCAN-colon screening
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ferent methods of CRC screening in our country and is
used to estimate the costs, colonoscopy and CT colonog-
raphy capacity requirements and effects of colonoscopy
and CT colonography screening versus other screening
programmes[53].
Ethical approval
Ethical approval was obtained from the Dutch Health
Council (2009/03WBO, The Hague, The Netherlands).
Data analysis
We will calculate the participation rate as the number of
participants undergoing the screening test relative to the
total number of all eligible invitees. We will compare the
participation rate between the three screening pro-
grammes, and express it as relative participation rates,
calculating corresponding 95% confidence intervals,
using colonoscopy screening with a prior consultation at
the outpatient clinic as the reference strategy.
We will test the null hypothesis of no difference in par-
ticipation rate using chi-square test statistics. We will also
calculate a conditional relative participation rate using
logistic regression modelling, accounting for baseline
variables. If the overall hypothesis of no difference is
rejected, we will test the null hypothesis of a difference in
mode of invitation to direct colonoscopy. Additionally,
we will test the null hypothesis of no difference in partici-
pation between CT colonography screening and direct
colonoscopy screening.
The detection rate of the screening test is defined as the
proportion of screenees with detected advanced neopla-
sia. Advanced neoplasia comprises all carcinomas and
advanced adenomas together. An advanced adenoma is
defined as an adenoma ≥ 10 mm, with villous histology
(≥25% villous) or with high grade dysplasia. The most
advanced detected lesion per screenee will be used to cal-
culate the detection rate.
The diagnostic yield per 100 invitees is defined as the
proportion of screenees with detected advanced neopla-
sia relative to all eligible invitees.
Sample size
We anticipate a participation rate of 22.5% in colonos-
copy screening with a prior consultation at the screening
centre, a participation rate of 27.5% with prior consulta-
tion by telephone, and a participation rate of 35% in the
CT colonography group (based on the participation rate
of FS screening in the Netherlands)[17]. Including 7,500
participants in the trial will then achieve a power exceed-
ing 99% to reject the null hypothesis of no difference,
using a 2 degrees of freedom Chi-Square test with a sig-
nificance level set at 0.05.
These numbers will lead to a 98% power to reject sub-
sequently the hypothesis of no difference in participation
for the two consultation modes with direct colonoscopy,
and a power exceeding 99% for the two other pair wise
comparisons between screening programmes.
Discussion
The optimal screening test is still under debate. Stool-
based tests and FS are considered as suboptimal tests.
DCBE and capsule endoscopy are not recommended for
CRC screening, because of its inferior diagnostic sensitiv-
ity.
Colonoscopy and CT colonography are the most accu-
rate colonic exams and screening options by which
inspection of the entire colon is allowed. Prospective data
on the effectiveness (CRC mortality reduction) of popula-
tion based screening programmes by colonoscopy and
CT colonography are lacking. The effectiveness of a
screening programme is directly influenced by the partic-
ipation rate. It is expected that the participation rate of
CT colonography screening is higher than with colonos-
copy screening, because of the lower burden of the proce-
dure. However, all CT colonography positives will need
colonoscopy for confirmation and therapy or need sur-
veillance which can lower the participation rate to the
total CT colonography programme. It is not known to
what extent this would influence participation rate.
This study will evaluate the efficacy of a colorectal can-
cer screening programme in the Netherlands using
colonoscopy and CT colonography as a screening
method. It will show whether participants are well-
informed about the screening programme and what fac-
tors would influence (non-)participation. If this study
shows that a prior consultation by telephone instead of a
prior consultation at the outpatient clinic in colonoscopy
screening has a positive effect on the participation rate,
this would contribute to the effectiveness of future
screening programmes.
This study will provide information on the uptake of a
population screening by colonoscopy and CT colonogra-
phy and on factors influencing the uptake. Furthermore,
this study will give insight into concerns on CT colonog-
raphy and especially on colonoscopy screening including
burden of the procedures, risks and costs. As other
screening options have already been investigated, this
study will enable to determine the most cost-effective
screening method for CRC in the Netherlands.
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